Myriad Genetics launched the FirstGene® Multiple Prenatal Screen, a lab test designed to run four prenatal genetic screens simultaneously as early as 8 weeks. The product positions the company with a differentiated workflow for early prenatal testing, which is modestly positive for sentiment but unlikely to be market-moving on its own.
Myriad Genetics launched the FirstGene® Multiple Prenatal Screen, a lab test designed to run four prenatal genetic screens simultaneously as early as 8 weeks. The product positions the company with a differentiated workflow for early prenatal testing, which is modestly positive for sentiment but unlikely to be market-moving on its own.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
